SCHEMBL2932073

SCHEMBL2932073

CCCCN(CCCC)C(=O)c1cc(C=O)ccc1OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
APP P05067 4/20 0.49
KDM4E B2RXH2 2/20 0.49
ALDH1A1 P00352 2/20 0.49
POLB P06746 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
TRPM8 Q7Z2W7 2/20 0.48
LMNA P02545 2/20 0.45
MAPT P10636 1/20 0.45
NPC1 O15118 1/20 0.44
CYP2C9 P11712 1/20 0.44
RAB9A P51151 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
MAOA P21397 1/20 0.42
MAOB P27338 1/20 0.42
TACR2 P21452 1/20 0.42
FOLH1 Q04609 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2934881 0.97 APP (0.48) APPKDM4EALDH1A1POLBL3MBTL1
SCHEMBL2928136 0.95 APP (0.47) APPKDM4EALDH1A1POLBL3MBTL1
SCHEMBL2932518 0.86 CYP2C9 (0.47) ALDH1A1MAPTNPC1CYP2C9RAB9A
SCHEMBL2929421 0.85 KDM4E (0.54) APPKDM4EALDH1A1POLBL3MBTL1
SCHEMBL2928085 0.83 PSEN1 (0.46) TACR2
SCHEMBL31056340 0.81 APP (0.58) APPKDM4EALDH1A1POLBL3MBTL1
SCHEMBL2932061 0.81 ALDH1A1 (0.52) APPKDM4EALDH1A1POLBL3MBTL1
SCHEMBL1648045 0.79 ALDH1A1 (0.73) KDM4EALDH1A1POLBL3MBTL1LMNA
SCHEMBL6811278 0.79 KDM4E (0.46) APPKDM4EALDH1A1POLBL3MBTL1
SCHEMBL2931028 0.79 ALDH1A1 (0.49) APPALDH1A1POLBMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1313731-B1 THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT UCB SA (BE) 2010-09-29 EP disclosed
US-6740670-B2 SUCH AS 5-(((3-(N-METHYL-N-PHENYLAMINO)CARBONYL-4-(PHENYL-METHOXY)) -PHENYL)METHYLENE)-4-OXO-2-THIOXO-3-THIAZOLIDINE-ACETIC ACID OXFORD GLYCOSCIENCES (UK) LTD. (GB) 2004-05-25 US disclosed
US-20030216453-A1 Thiazolidine derivatives and its use as antifungal agent OXFORD GLYCOSCIENCES (UK) LTD (GB) 2003-11-20 US disclosed
EP-1313731-A1 THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT Oxford GlycoSciences (UK) Limited (GB) 2003-05-28 EP disclosed
WO-2002022612-A1 THIAZOLIDINE DERIVATIVES AND ITS USE AS ANTIFUNGAL AGENT OXFORD GLYCOSCIENCES (UK) LIMITED (GB) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216453-A1 Thiazolidine derivatives and its use as antifungal agent CYP3A7, TAS2R7, OXSR1 APP 4343/4885KDM4E 3752/4885ALDH1A1 2527/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.